Towards clinical grating-interferometry mammography

Carolina Arboleda1,2, Zhentian Wang1,2, Konstantins Jefimovs1,2, Thomas Koehler3, Udo Van Stevendaal4, Norbert Kuhn5, Bernd David3, Sven Prevrhal3, Kristina Lång1,2, Serafino Forte5, Rahel Antonia Kubik-Huch5, Cornelia Leo6, Gad Singer7, Magda Marcon8, Andreas Boss8, Ewald Roessl3, Marco Stampanoni1,2

Abstract

Objectives Grating-interferometry-based mammography (GIM) might facilitate breast cancer detection, as several research works have demonstrated in a pre-clinical setting, since it is able to provide attenuation, differential phase contrast, and scattering images simultaneously. In order to translate this technique to the clinics, it has to be adapted to cover a large field-of-view within a clinically acceptable exposure time and radiation dose.

Methods We set up a grating interferometer that fits into a standard mammography system and fulfilled the aforementioned conditions. Here, we present the first mastectomy images acquired with this experimental device.

Results and conclusion Our system performs at a mean glandular dose of 1.6 mGy for a 5-cm-thick, 18%-dense breast, and a field-of-view of 26 × 21 cm2. It seems to be well-suited as basis for a clinical-environment device. Further, dark-field signals seem to support an improved lesion visualization. Evidently, the effective impact of such indications must be evaluated and quantified within the context of a proper reader study.

Key Points

- Grating-interferometry-based mammography (GIM) might facilitate breast cancer detection, since it is sensitive to refraction and scattering and thus provides additional tissue information.
- The most straightforward way to do grating-interferometry in the clinics is to modify a standard mammography device.
- In a first approximation, the doses given with this technique seem to be similar to those of conventional mammography device.

Keywords Mammography · Phase contrast · Interferometry

Abbreviations

DBT Digital breast tomosynthesis
DF Dark-field
DPC Differential phase-contrast
FOV Field-of-view
GI Grating interferometry
GIM Grating-interferometry-based mammography
MGD Mean glandular dose
MRI Magnetic resonance imaging
PC Phase-contrast
PCI X-ray phase-contrast imaging
SNR Signal-to-noise ratio
US Ultrasonography
**Introduction**

Mammography remains the mainstay imaging technique for screening and clinical evaluation of breast cancer [1] and the only modality that has demonstrated to decrease the number of deaths caused by breast cancer. However, mammography has limited sensitivity in dense breasts, due to the masking effect of overlapping tissue, and at the same time, women with dense breasts have a higher risk of breast cancer [2]. Notwithstanding, there is no consensus either on whether additional examinations should be carried out or on which in particular for women with dense breasts [3]. Potential additional or alternative methods include ultrasonography (US), magnetic resonance imaging (MRI), digital breast tomosynthesis (DBT), molecular breast imaging [4], and, maybe in the future, X-ray phase-contrast imaging (PCI). Both US and MRI can increase the sensitivity in dense breasts compared with mammography, but at the cost of reduced specificity [5, 6]. On the other hand, DBT has been shown to increase the performance in screening, but still has some limited sensitivity in extremely dense breasts, especially in the case of non-spiculated tumors [7], so PCI might hold potential as an alternative technique for mammography.

Unlike standard radiography, simply capable of measuring beam attenuation, PCI is sensitive to the refraction (i.e., change in direction or phase shift of the incoming X-ray beam) induced by the sample, providing a phase-contrast (PC) signal. In addition, grating-interferometry-based PCI (GI) is able to measure how much the sample scatters, yielding the so-called dark-field (DF) signal and delivering even more complementary information, which has shown to have potential for breast lesion detection [8]. In fact, in a reader study with 33 mastectomy samples, it was concluded that the GI images evidenced superior quality, with increased sharpness, lesion delineation, and microcalcification visibility [9]. However, it should be kept in mind that this study was performed at doses higher than the ones accepted in the clinics. Similarly, Anton et al [10] measured six mastectomy samples with GI and demonstrated that the DF images yield higher contrast of important structures compared with attenuation.

These results have motivated the transfer of the GI technology to the clinics [11–13], which constitutes an engineering challenge. This task requires the adaptation of the method to cover a large field-of-view (FOV) within a limited exposure time, deliver a clinically acceptable dose [14], fulfill the ergonomic requirements, avoid increasing patient discomfort, and, most importantly, yield a higher diagnostic performance [15]. Taking all this into account, a straightforward strategy is to design a GI that fits into a standard mammography device [16]. In this work, we describe the technical properties of a novel clinically compatible GI-based mammography device based on an existing system and its first usage imaging mastectomy samples.

**Materials and methods**

A device similar to a Microdose SI (Philips Diagnostic X-ray and Mammography Solutions) [15] was selected as the hosting device for the clinically compatible GI, mainly because of its slit-scanning geometry. The latter configuration allows using relatively small-area gratings (5 cm × 7 cm) to cover the required FOV (Fig. 1), which is rather large (26 × 21 cm²) to be spanned with a single grating, considering the corresponding engineering limitations [18]. The GI design parameters (Table 1) were optimized for the differential phase-contrast (DPC) signal following the procedure described in [17], but using a larger inter-grating distance to improve setup sensitivity, which could be achieved by modifying the pre-collimator height. The total setup length refers to the G0–G2 distance, whereas the design energy corresponds to the energy of the incoming spectrum the gratings were designed for to obtain the best achievable GI performance [17].

Gratings were mounted on a support that allowed for bending to compensate for the oblique incidence of the X-rays (patent number PCT/EP2018/062407) [19] and had a mask that matched the pre-collimator design so that bending could be supported while keeping the flux unaffected (Fig. 2c). For optimal grating alignment, vertical translation of the G0 support (Fig. 2a) was controlled by two piezoelectric motors, and the G1-G2 frames (Fig. 2b) were rotated using micrometer-precision screws. In addition, a dedicated biocompatible breast support that could accommodate the interferometer was commissioned (Fig. 2d).

The clinical study was approved by the responsible Ethical committee (EKNZ 2015‘132) and written informed consent from the included patients was obtained. Four mastectomy specimens were imaged directly after surgical extraction at a tube voltage of 38 kVp with a total scanning time of 13.4 s in an uncompressed state. Although the latter is still above the typical measuring times for slit-scanning systems (5–8 s), it is still clinically compatible [14]. These exposure settings were selected in order to maximize the contrast-to-noise ratio on the PC and DF images, since due to their noise behavior, more incoming flux than in standard attenuation-based mammography is required to get the same signal quality [17].

Attenuation, DPC, and DF images were reconstructed with an iterative algorithm [16]. The attenuation and DPC signals were further fused [20] and processed with a contrast-boosting algorithm [21]. The latter was applied to the attenuation signal alone as well.

The air kerma and half-value layer were measured with a RaySafe device and used to calculate the mean glandular dose (MGD) for each sample according to the European Guidelines [14].
Results

In this work, we successfully retrofitted a GI on a standard mammography device. Figures 3 and 4 show the first images obtained with the device. Figure 3 illustrates the attenuation, DPC, and DF signals as produced by the GI add-on. Figure 4 presents the fusion image (obtained by combining the attenuation and DPC signals according to [20]) and the DF signal from another sample.

As evidenced by Figs. 3 and 4, the additional imaging signals provided with GI can yield complementary information at radiation doses comparable to conventional mammography, which could increase the diagnostic performance of the latter. In Fig. 3, it can be observed that the DPC signal facilitates the delineation of edges; this is due to the fact that this signal enhances high spatial frequency components [20], which could contribute to an increased sensitivity for breast cancer detection. The DF signal carries further complementary information, since it can generate contrast enhancement due to the scattering of both tumor masses and microcalcifications. In Fig. 4, the DF signal of the tumor mass was especially prominent showing a higher signal than the fibro-glandular tissue. This holds true potential in the detection of tumors that are embedded in dense breast tissue. Also, the quantification of the DF signal might also enable a non-invasive discrimination of microcalcifications, which would be of great clinical value [10, 22–24].

The corresponding thicknesses, pathological diagnoses, and estimated MGD values for the measured samples are reported in Table 2. The measured air kerma and half-value layer were 5.9 mGy and 0.5 mm Al, respectively. These values were used to calculate the MGD for each sample assuming an 18% glandular density, since the exact breast density was unknown and this is the highest-occurrence density in the population [25]. The resulting MGD values fully comply with the limits established by the European guidelines for the 5-cm breasts, since they report a maximum acceptable dose of less than 2.5 mGy for a 5.3-cm breast. However, the calculated

Table 1 GI prototype design parameters

| Parameter              | Value |
|------------------------|-------|
| GI length (cm)         | 55.6  |
| G1-G2 distance (cm)    | 6.65  |
| G0 period (μm)         | 19.92 |
| G1 period (μm)         | 4.73  |
| G2 period (μm)         | 2.68  |
| Design energy (keV)    | 26    |
MGD values are slightly above the maximum for the 4-cm specimens, since the Guidelines report a maximum of less than 2.0 mGy for 4.5-cm breasts [14]. However, it is important to consider that a certain breast density (i.e., 18%) was assumed for this dose calculation. If the samples happened to have a glandular density of 36% instead, the dose would be clinically acceptable for the thinner specimens as well. In addition, although the estimated MGDs are slightly higher than those reported for conventional mammography, the values appear similar to those reported for breast tomosynthesis [26].

Discussion

The obtained results demonstrate the feasibility of a clinical application of GIM. From the engineering point of view, the
most challenging part of commissioning a GI on an existing scanning-based mammography device was to develop a solid grating holder that allowed keeping the gratings aligned during operation and protected from the vibrations caused by the movement of the scanning arm. In addition to that, it is important to consider that since G0 and G2 are gold gratings, each of them attenuates half of the incoming photons. This means that to obtain SNR values comparable to a standard mammographic setup, it is necessary to increase the exposure times accordingly. The larger the exposure times can be made, while keeping the dose under the acceptable limit [14], the better the quality of the DF and DPC signals. However, it is important to keep in mind that larger exposure times might cause increased patient discomfort and motion artifacts. These aspects shall be considered for the use of this system in an in vivo setting.

Another critical issue is the GI sensitivity that is proportional to the distance between G1 and G2. The fact that this investigational device was commissioned on an existing clinical setup obliged us to fix a few important parameters (like source-to-detector distance, for instance) which imposed additional constraints to the system design. If a GIM device were to be built from scratch, a different geometry could be selected. The disadvantage of the latter option would be that the time between development and transfer to the clinics would become substantially longer.

The presented DF images still have some artifacts, due to the fact that this signal is the most sensitive to noise and vibrations [19], but should only be seen as providing complementary information to that of the anatomical attenuation/fused images, in the same manner as diffusion-weighted images provide supplemental information to anatomical MRI sequences. Nevertheless, further work on improving the DF image quality, e.g., by optimizing image reconstruction and post-processing methods, will increase the usability of this signal.

The purpose of fusing the attenuation and DPC signals (Fig. 4a) is to present an attenuation-like image with additional refraction information to radiologists, so that they can use their experience and knowledge to assess the innovative signals provided with GIM [9]. Notwithstanding, it is a future work to assess in a large reader study whether it is more useful to present the images combined or separately (Fig. 3).

### Table 2 Sample characteristics

| Sample | Thickness (cm) | Histological diagnosis | MGD (mGy) |
|--------|----------------|------------------------|-----------|
| 1      | 5 cm           | 18-mm and 4-mm multicentric invasive ductal carcinoma + DCIS | 1.6       |
| 2      | 5 cm           | 14-mm and 14-mm multicentric invasive ductal carcinoma + DCIS | 1.6       |
| 3      | 4 cm           | 25-mm invasive ductal carcinoma + DCIS | 2.0       |
| 4      | 4 cm           | 38-mm invasive papillary carcinoma mixed with invasive ductal carcinoma + DCIS | 2.0       |

---

Fig. 4 GIM images of sample 4. a Attenuation+DPC fused image. b DF. The DF image provides a strong signal in the tumor area delineated by the red square, where even calcifications, which are hardly visualized in the fused image, can be observed.

---

Eur Radiol (2020) 30:1419–1425
A careful investigation of the optimal acquisition parameters for each different breast thickness and density will be carried out, since most likely voltages higher than those used in traditional mammography would yield better GI outcomes [8]. In this study, the same exposure settings were used for all the samples, in spite of them having different thicknesses and densities. However, it is important to remember that the variation in the latter two quantities is less prominent in specimen radiography compared with whole breast imaging. In fact, in this particular study, sample thickness ranged from 4 through 5 cm. The decision to always use the same exposure settings was made based on the results of the optimization procedure carried out in [17], in which it was found that the highest flux delivered by the hosting device would yield the best DF and PC quality. However, it might be potentially possible to obtain higher fluxes at lower voltages, in a way that the attenuation CNR would not be sacrificed for the sake of the two additional signals. Before intending to use the system on patients, more mastectomy samples are to be measured to do an accurate evaluation of the diagnostic contribution of GI.

In conclusion, we show first promising results of the successful implementation of a full-FOV clinically compatible GI based on a standardly available FFDM system that might provide complementary information for breast cancer diagnosis. Our approach presently still operates at a higher dose level compared with other systems available on the market. Therefore, the real challenge will be to demonstrate that cancer detection can be considerably increased at this higher dose. However, it is also important to keep in mind that a proper dose calculation, using the Monte Carlo simulations and the appropriate breast phantom, must be carried out as well.

The investigational device has been successfully commissioned and will be soon used for an upcoming in vivo pilot study.

Acknowledgments The authors thank Gordan Mikuljan for his help during setup commissioning.

Funding This study has received funding by the ERC grant ERC-2012-StG 310005 “PhaseX,” the SNF-Sinergia CRS112-154472 “MedXPhase” and SNF-Sinergia CRSI5_183568 “GI-BCT” grants, and the SNF R’Equip grant 206021_177036 “Displacement Talbot Lithography for micro and nanopatterning.”

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Prof. Dr. Marco Stampanoni.

Conflict of interest The authors of this manuscript declare relationships with the following companies: Philips.

Statistics and biometry No complex statistical methods were necessary for this paper.

Informed consent Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval Institutional Review Board approval was obtained.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

References

1. Independent UK Panel on Breast Cancer Screening (2012) The benefits and harms of breast cancer screening: an independent review Lancet 380(9855):1778–1786
2. Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356:227–236
3. Slanetz PJ, Freer PE, Birdwell RL (2015) Breast density legislation—practical considerations. N Engl J Med 372:593–595
4. Ho JM, Jaerjee N, Covarrubias GM, Ghesani M, Handler B (2014) Dense breasts: a review of legislation and available supplemental screening options. AJR Am J Roentgenol 203(2):449–456
5. Lee CI, Cevik M, Alagoz O et al (2015) Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology 274(3):772–780
6. Gweon HM, Cho N, Kim SY et al (2017) Management for BI-RADS category 3 lesions detected in preoperative breast MR imaging of breast cancer patients. Eur Radiol 27:3211–3216
7. Kopans DB (2013) Digital breast tomosynthesis: a better mammogram. Radiology 267(3):968–969
8. Stampanoni M, Wang Z, Thüring T et al (2011) The first analysis and clinical evaluation of native breast tissue using differential phase-contrast mammography. Invest Radiol 46(12):801–806
9. Hauser N, Wang Z, Kubik-Huch R et al (2013) A study on mastectomy samples to evaluate breast imaging quality and potential clinical relevance of differential phase contrast mammography. Invest Radiol 49(3):131–137
10. Anton G, Bayer F, Beckmann MW et al (2013) Grating-based dark-field imaging of human breast tissue. Z Med Phys 23(3):228–235
11. Scherer K, Willer K, Gromann L et al (2015) Toward clinically compatible phase-contrast mammography. PLoS One 10(6):e0130776
12. Munro PR, Ignatyev K, Speller RD, Olivo A (2010) Design of a novel phase contrast X-ray imaging system for mammography. Phys Med Biol 55:4169–4185
13. Olivo A, Gikoumas S, Endrizzi M et al (2013) Low-dose phase contrast mammography with conventional X-ray sources. Med Phys 40(9):090701
14. Perry N, Broeders M, De Wolf C, Törnberg S, Holland R, Von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, fourth edition, European communities
15. Roessl E, Daerr H, Koecher T, Martens G, van Stevendaal U (2014) Clinical boundary conditions for grating-based differential phase-contrast mammography. Philos Trans A Math Phys Eng Sci 372:20130033
16. Koehler T, Daerr H, Martens G et al (2015) Slit-scanning differential X-ray phase-contrast mammography: proof-of-concept experimental studies. Med Phys 42(4):1959–1965
17. Arboleda C, Wang Z, Koehler T et al (2017) Sensitivity-based optimization for the design of a grating interferometer for clinical X-ray phase contrast mammography. Opt Express 25(6):6349–6364
18. Kagias M, Wang Z, Guzenko VA, David C, Stampanoni M, Jefimovs K (2019) Fabrication of Au gratings by seedless electroplating for X-ray grating interferometry. Mater Sci Semicond Process 92:73–79
19. Revol V, Kottler C, Kaufmann R et al (2011) X-ray interferometer with bent gratings: towards larger fields of view. Nucl Instrum Methods Phys Res Sect A 648:S302–S305
20. Roessl E, Koehler T, van Stevendaal U et al (2012) Image fusion algorithm for differential phase contrast imaging. Proc. SPIE 8313. Medical Imaging 2012: Physics of Medical Imaging 831354
21. Stahl M, Aach T, Dippel S (2000) Digital radiography enhancement by nonlinear multiscale processing. Med Phys 27(1):56–65
22. Scherer K (2016) Microcalcification assessment with dark-field mammography. In: Scherer K (ed) Grating-based X-ray phase-contrast mammography, 77–93, Springer
23. Wang Z, Hauser N, Singer G et al (2014) Non-invasive classification of microcalcifications with phase contrast X-ray mammography. Nat Commun 5:3797
24. Wang Z, Hauser N, Singer G et al (2016) Correspondence: reply to ‘Quantitative evaluation of X-ray dark-field images for microcalcification analysis in mammography’. Nat Commun 7:10868
25. Fredenberg E, Dance DR, Willsher P et al (2013) Measurement of breast-tissue x-ray attenuation by spectral mammography: first results on cyst fluid. Phys Med Biol 58(24):8609
26. Genaro G, Bernardi D, Houssami N (2018) Radiation dose with digital breast tomosynthesis compared to digital mammography: per-view analysis. Eur Radiol 28(2):573–581

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.